title: Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study.
abstract: The efficacy of continuous oral cytarabine ocfosfate (YNK01) (300 mg/day) in combination with interferon alpha (IFNalpha, 5x10(6) IU/day) was evaluated in patients with advanced chronic myelogenous leukemia, who previously failed to respond to IFNalpha-based therapies. Dose escalations up to 900 mg YNK01 were allowed in patients who failed to respond. In view of our results, four patients developed a complete hematological response after YNK01 was started. Among those who initially responded to YNK01, one complete cytogenetic response was achieved 18 months later. Although the data are preliminary, this is the first study showing that continuous administration of YNK01 along with IFNalpha is effective in patients with advanced chronic myelogenous leukemia.
authors.affiliation: Department of Internal Medicine, University Hospital, Anichstrasse 35, 6020, Innsbruck, Austria. thomas.kuehr@uibk.ac.at
authors.forename: T
authors.initials: T
authors.lastname: Kühr
authors.forename: W
authors.initials: W
authors.lastname: Eisterer
authors.forename: U
authors.initials: U
authors.lastname: Apfelbeck
authors.forename: W
authors.initials: W
authors.lastname: Linkesch
authors.forename: O
authors.initials: O
authors.lastname: Bechter
authors.forename: A
authors.initials: A
authors.lastname: Zabernigg
authors.forename: K
authors.initials: K
authors.lastname: Geissler
authors.forename: G
authors.initials: G
authors.lastname: Barbieri
authors.forename: C
authors.initials: C
authors.lastname: Duba
authors.forename: G
authors.initials: G
authors.lastname: Gastl
authors.forename: J
authors.initials: J
authors.lastname: Thaler
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001088:Arabinonucleotides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003568:Cytidine Monophosphate / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D001088:Arabinonucleotides; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C061162:1-arabinofuranosylcytosine-5'-stearylphosphate; D003568:Cytidine Monophosphate